A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy

Cancer Research

Volumn 72, Issue 8, 2012, Pages 1986-1995

  Cho, Hyun Il ^a   Reyes Vargas, Eduardo ^c   Delgado, Julio C ^c   Celis, Esteban ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; EPITOPE; FREUND ADJUVANT; HGP 100 25; IMMUNOGLOBULIN G; INTERLEUKIN 2; INTERLEUKIN 2 INTERLEUKIN 2 RECEPTOR ANTIBODY COMPLEX; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; PEPTIDE VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; PROGRAMMED DEATH LIGAND 1 MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL EXPANSION; CELL SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; LONG TERM SURVIVAL; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; T LYMPHOCYTE; THERAPY EFFECT; TUMOR VOLUME; WHOLE BODY RADIATION;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PROGRAMMED CELL DEATH 1 RECEPTOR; VACCINES, SUBUNIT;

EID: 84860191757     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3246     Document Type: Article

References (43)

1. Cerottini JC, Brunner KT. Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv Immunol 1974;18:67-132.
2. Lowin B, Krahenbuhl O, Muller C, Dupuis M, Tschopp J. Perforin and its role in T lymphocyte-mediated cytolysis. Experientia 1992;48:911-20.
3. Berke G. The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol 1994;12:735-73. (Pubitemid 24140430)
4. Blankenstein T, Qin Z. The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Oppin Immunol 2003;15:148-54. (Pubitemid 36287519)
5. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993;11:403-50. (Pubitemid 23115014)
6. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277-86. (Pubitemid 28357756)
7. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24:175-208.
8. Slingluff CL Jr, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, et al. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv Immunol 2006;90:243-95. (Pubitemid 43786236)
9. Redmond WL, Sherman LA. Peripheral tolerance of CD8 T lymphocytes. Immunity 2005;22:275-84. (Pubitemid 40387470)
10. Mueller DL. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010;11:21-7.
11. Dudley ME, Nishimura MI, Holt AK, Rosenberg SA. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J Immunother 1999;22:288-98. (Pubitemid 29309961)
12. Buteau C, Markovic SN, Celis E. Challenges in the development of effective peptide vaccines for cancer. Mayo Clinic Proceed 2002;77:339-49. (Pubitemid 34260742)
13. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308. (Pubitemid 351430867)
14. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21:233-40.
15. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity 2008;29:848-62.
16. Boyman O, Letourneau S, Krieg C, Sprent J. Homeostatic proliferation and survival of naive and memory T cells. Eur J Immunol 2009;39:2088-94.
17. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009;9:480-90.
18. Dudley ME, Rosenberg SA. Adoptive cell transfer therapy. Semin Oncol 2007;34:524-31. (Pubitemid 350236303)
19. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917-24.
20. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005;202:907-12. (Pubitemid 41396891)
21. Powell DJ Jr, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patientswith metastatic melanomafollowing lymphodepletion. J Immunol 2006;177:6527-39. (Pubitemid 44628872)
22. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9.
23. Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010;33:1-7.
24. Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Curr Protoc Immunol 2001;Chapter 20:Unit 20 1.
25. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-80. (Pubitemid 37040391)
26. Cho HI, Celis E. Optimized peptide vaccines eliciting extensive CD8 Tcell responses with therapeutic antitumor effects. Cancer Res 2009;69:9012-9.
27. Storkus WJ, Zeh HJ 3rd, Salter RD, Lotze MT. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother Emphasis Tumor Immunol 1993;14:94-103. (Pubitemid 23297420)
28. van Stipdonk MJ, Badia-Martinez D, Sluijter M, Offringa R, van Hall T, Achour A. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res 2009;69:7784-92.
29. Gold JS, Ferrone CR, Guevara-Patino JA, Hawkins WG, Dyall R, Engelhorn ME, et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003;170:5188-94. (Pubitemid 36554751)
30. Assudani D, Cho HI, DeVito N, Bradley N, Celis E. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res 2008;68:9892-9.
31. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006;311:1924-7.
32. Verdeil G, Marquardt K, Surh CD, Sherman LA. Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc Natl Acad Sci U S A 2008;105:16683-8.
33. Blank C, Brown I, Peterson AC, SpiottoM, Iwai Y,Honjo T, et al. PDL1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004;64:1140-5. (Pubitemid 38176921)
34. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089-96. (Pubitemid 40216472)
35. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007;8:239-45. (Pubitemid 46745373)
36. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994;153:5586-92. (Pubitemid 24377694)
37. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996;156:3308-14. (Pubitemid 26123546)
38. Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010;70:6725-34.
39. Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res 2011;17:5343-52.
40. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 2007;117:2197-204. (Pubitemid 47219564)
41. Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, et al. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patientswith metastatic melanoma and metastatic renal cell cancer. J Immunother 2008;31:569-76.
42. Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology 2002;16:11-20.
43. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res 2007;13:5280-9. (Pubitemid 47510351)